Physician profile
Larry M Einbinder
NPI 1609848936
$1,957.12
in general payments reported to CMS, 2019-2025
28 companies · $16.14 in 2025
The $16.14 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $476 · 2020: $257 · 2021: $836 · 2022: $283 · 2023: $63.82 · 2024: $25.20 · 2025: $16.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $650.82 | 2019-2024 | |
| Abbvie INC. | $341.17 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $130.39 | 2021 | |
| Upsher-Smith Laboratories LLC | $106.39 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $88.33 | 2019-2020 | |
| Lundbeck LLC | $81.88 | 2019-2021 | |
| Ucb, INC. | $53.49 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $46.80 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $42.31 | 2020 | |
| Ge Healthcare | $42.27 | 2019 | |
| Genzyme Corporation | $37.60 | 2021 | |
| Xeris Pharmaceuticals, INC. | $35.47 | 2021 | |
| Emd Serono, INC. | $28.67 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $27.64 | 2021 | |
| Acorda Therapeutics, INC | $24.60 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $24.53 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.63 | 2021 | |
| Pfizer INC. | $19.83 | 2021 | |
| Grifols USA, LLC | $19.50 | 2019 | |
| Allergan, INC. | $18.71 | 2020 | |
| Assertio Therapeutics, INC. | $16.54 | 2020 | |
| Csl Behring | $16.10 | 2021 | |
| Avion Pharmaceuticals | $15.62 | 2021 | |
| Acadia Pharmaceuticals INC | $14.74 | 2019 | |
| Adamas Pharmaceuticals, INC. | $14.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.47 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.69 | 2021 | |
| Zyla Life Sciences, INC. | $11.60 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Larry Einbinder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.